Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial

Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review

(2018) Mallika Lala et al.   ORAL ONCOLOGY

Immune Checkpoint Inhibition in Head and Neck Cancer

(2018) Martin David Forster et al.   Frontiers in Oncology

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

(2018) Ezra E W Cohen et al.   LANCET

Prevalence of Human Papillomavirus Type-16 in Head and Neck Cancer Among the Chinese Population: A Meta-Analysis

(2018) Lanwei Guo et al.   Frontiers in Oncology

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

(2017) Kevin J Harrington et al.   LANCET ONCOLOGY

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence of Human Papillomavirus in Oropharyngeal Cancer

(2015) Andrew P. Stein et al.   CANCER JOURNAL

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

(2015) Jean-Pascal H Machiels et al.   LANCET ONCOLOGY

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial

(2014) J. B. Vermorken et al.   ANNALS OF ONCOLOGY

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck†

(2014) T. Y. Seiwert et al.   ANNALS OF ONCOLOGY

Oropharyngeal cancers: Relationship between epidermal growth factor receptor alterations and human papillomavirus status

(2014) H. Mirghani et al.   EUROPEAN JOURNAL OF CANCER

A comprehensive evaluation of human papillomavirus positive status and p16INK4a overexpression as a prognostic biomarker in head and neck squamous cell carcinoma

(2014) ZEYI DENG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

P16INK4Aas a surrogate biomarker for human papillomavirus-associated oropharyngeal carcinoma: Consideration of some aspects

(2013) Hongzhi Wang et al.   CANCER SCIENCE

Biostatistics Primer: What a Clinician Ought to Know: Hazard Ratios

(2011) Helen Barraclough et al.   Journal of Thoracic Oncology

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

(2011) Jean-Pascal Machiels et al.   LANCET ONCOLOGY

Targeted therapies in squamous cell carcinoma of the head and neck

(2009) Kathryn A. Gold et al.   CANCER